NeoStem Announces Launch of Government Affairs Initiative
News Apr 04, 2007
NeoStem has announced the launch of a “Government Affairs” initiative to lobby key members of the federal government on the growing threat to the thousands of first responders from radiation exposure following a possible nuclear assault.
NeoStem’s “Government Affairs” initiative is a concerted effort to leverage the Company’s next generation services to allow the thousands of first responders, including firemen, police officers and National Guardsmen, across the nation to store their own, genetically-matched adult stem cells to treat bone marrow failure caused by nuclear radiation, a common cause of death following exposure.
The use of adult stem cells to treat diseased bone marrow has been a proven therapy for more than 40 years.
“We have an obligation to provide every possible advantage to the thousands of brave men and women who are at the greatest risk of radiation exposure,” said Arlene Graime, NeoStem’s Director of Government Affairs and Special Projects.
“NeoStem is fully committed to lobbying key members of the state and federal government to give first responders the advantage of collecting and storing their own stem cells for personal therapeutic use.”
Ms. Graime was recently hired by NeoStem to spearhead initiatives with the Department of Defense and key Congressional committees to raise visibility for NeoStem’s proprietary adult stem cell collection, processing and storage technology.
Additionally, NeoStem named Dr. Neil C. Livingstone, a noted expert on national security, to the Company’s Advisory Board. Dr. Livingstone has served on advisory panels to The Secretary of State, The Chief of Naval Operations, and The Pentagon.
He has testified before Congress and delivered more than 500 major addresses in the U.S. and abroad, including recent speeches at The House of Commons and The United Nations.
“NeoStem is fully committed to exploiting our next generation biotech services to both assist on national security issues and to continually build shareholder value,” said Robin Smith, M.D., Chief Executive Officer of NeoStem. “We believe that this concerted effort to access key government officials will significantly accelerate that mission.”
NeoStem is developing a nationwide health-industry network to capitalize on the predicted $8.5 billion stem cell therapeutics industry.